2,539
Views
198
CrossRef citations to date
0
Altmetric
Review

Mild cognitive impairment and its management in older people

, , &
Pages 687-693 | Published online: 10 Apr 2015

Abstract

Mild cognitive impairment (MCI) is a common condition in the elderly. It is characterized by deterioration of memory, attention, and cognitive function that is beyond what is expected based on age and educational level. MCI does not interfere significantly with individuals’ daily activities. It can act as a transitional level of evolving dementia with a range of conversion of 10%–15% per year. Thus, it is crucial to protect older people against MCI and developing dementia. The preventive interventions and appropriate treatments should improve cognitive performance, and retard or prevent progressive deficits. The avoidance of toxins, reduction of stress, prevention of somatic diseases, implementation of mental and physical exercises, as well as the use of dietary compounds like antioxidants and supplements can be protective against MCI. The modification of risk factors such as stopping smoking, as well as the treatment of deficiency in vitamins and hormones by correcting behaviors and lifestyle, can prevent cognitive decline in the elderly. The progressive increase in the growth rate of the elderly population can enhance the rate of MCI all over the world. There is no exact cure for MCI and dementia; therefore, further studies are needed in the future to determine causes of MCI and risk factors of progression from MCI to dementia. This will help to find better ways for prevention and treatment of cognitive impairment worldwide.

Background

The improvement of health care support has greatly extended the average life expectancy, which has resulted in a substantial increase in the number of individuals aged 65 years and above. Memory impairment is the usual consequence of the ageing process in the elderlyCitation1 and can be a marker of Alzheimer’s disease (AD)Citation2 and dementia. It presents with declines in both episodic and immediate memory. Episodic memory is the ability to recall recent experiences and events, and it decreases in the early stages of adulthood. Immediate memory also decreases with advancing age, and it is characterized by a lower ability of thinking and deciding.Citation3

The rate of memory impairment varies among different populations, which can be explained by the possible effects of factors including average age of respondents, type of questions asked, sex differences, educational level, and depression.Citation1 With the substantial increase in the incidences of dementia, early detection of possible precursors, diagnosis, treatment, and control of modifiable risk factors are important to reduce the rate of disease.Citation4

Cognition is a bodily function that is decreased by ageing when there is the impairment of memory, judgment, language, and attention.Citation5 It can occur due to neurodegenerative, vascular, and dysthymia/dysphoria problems.Citation6 Impaired cognition and reduced cognitive abilities can affect social, functional, and occupational activities.Citation5 The estimated prevalence of cognitive impairment, which varies widely in different research, can be attributed to the use of different definitions. Age-associated memory impairment and cognitive impairment–no dementia are more prevalent than mild cognitive impairment (MCI).Citation1

The prevalence of MCI is about four-times greater than dementia.Citation1 Petersen et al were the pioneers in introducing MCI.Citation7 MCI characteristics are declining and disturbance of cognition, minimal impairment of complex activities, ability to perform regular daily functions, and absence of dementia.Citation4 In typical MCI, memory impairmentCitation8Citation10 as well as cognitive decline are at a greater rate than expected for an individual’s ageCitation9,Citation10 and educational levelCitation9 without impairing daily activities.Citation8,Citation9 MCI is a transitional level between normal state of brain and dementiaCitation7,Citation11Citation14 with different features including amnestic MCI (aMCI), single-domain non-amnestic MCI, and multiple domain MCI.Citation6 The amnestic type is a prodromal stage of dementiaCitation7,Citation9 and presents itself predominantly with memory impairment.Citation6 While memory gets damaged in aMCI,Citation7,Citation15 general cognitive function and daily activities are normal.Citation7,Citation15,Citation16 Non-amnestic MCI accompanies deficits in cognitionCitation7 and motor performancesCitation17 without affecting memory.Citation7 Memory loss and cognitive decline occur in multiple-domain MCI.Citation6 Amnestic and multiple-domain pose an equal risk for progression towards AD.Citation6

Although MCI has a greater risk of progression to dementia,Citation1,Citation9,Citation18 sometimes it reverts to normal status or has no progression to dementia.Citation11,Citation18 It has been reported that up to 44% of patients with MCI at their first visit are estimated to return to normal after a year.Citation19 Various research indicate that the progression rate of MCI to dementia depends on factors such as the return to normal state,Citation19 the definitions of MCI applied, sample size, geographic region, the nature of individuals, cultural background, length of follow-up, neuropsychiatric symptoms, assessment procedures, and cutoff points when considering age and education.Citation18,Citation20

Cognitive impairment is a common problem in the elderlyCitation21,Citation22 that is associated with age,Citation8,Citation21,Citation23 with an occurrence rate of approximately 21.5–71.3 per 1,000 person-years in seniors.Citation8 MCI rates range from 3% to as high as 42% in population studies,Citation8 and from 6% to 85% in clinical settings.Citation6,Citation24 The MCI conversion rate to dementia is about 10% per year,Citation1,Citation6,Citation16,Citation21,Citation25Citation27 which is increased to 80%–90% after approximately 6 years.Citation28 It is estimated that a new case of dementia is added each 7 seconds.Citation21 The prevalence of dementia in the elderly population is between 1% to 2% per year.Citation11,Citation29 It is forecast that number of cases in the developing world will increase by 100% between 2001 and 2040.Citation21 It seems that the rate of dementia will increase from 9.4% in 2000 to 23.5% by 2050 in the population over 60 years of age.Citation30

It is projected that the number of elderly people in the world will increase by 21% in the next 50 years. The elderly population in the developing and developed countries will increase by 140% and 51% respectively. The growing rate of elderly people in the Asian and Pacific regions is faster than the past. Asia–Pacific is a region near the Western Pacific Ocean containing much of East Asia as well as Southeast Asia countries such as Australia, New Zealand, Pakistan, Indonesia, Malaysia, Philippines, Japan, India, Singapore, People’s Republic of China, Thailand, Sri Lanka, South Korea, Hong Kong SAR, and Chinese Taipei.Citation30 Among Asian countries, the difference in prevalence of MCI is greater than five-fold.Citation8,Citation20 The prevalence of MCI is increasing among developed and developing countries. Rapid demographic ageing in low- and middle-income countries makes it a priority to identify the people at the risk of developing dementia at early stages for targeting preventive interventions. MCI is an intermediate phase between normal ageing-related cognitive decline and dementia; therefore, the identification of MCI can play an important role in early intervention, prevention,Citation20 and proper treatments.Citation16

Until now, data are scarce for determining the type of cognitive decline, MCI, or dementia. It is necessary to investigate MCI in-depth and find new therapeutic methods and modifiable risk factors.Citation4 Although there are many risk factors (), the greatest risk factor for cognitive decline is age, but the exact cause is still unknown.Citation31

Table 1 Some of the possible mild cognitive impairment risk factors in the elderly

The identification of genetic risk factors increases the ability to identify individuals at a higher risk for developing cognitive impairment and/or its progression to dementia.Citation22 The progression into dementia is faster when there are concurrent co-morbid medical conditionsCitation32 and gross pathological changes.Citation6 MCI proceeds into dementia when amyloid plaques and neurofibrillary tangles deposit in the neocortex of the brain.Citation14 Apolipoprotein E (ApoE) epsilon 4 carrier can also enhance the risk of conversion from MCI to AD in individuals with cognitive decline.Citation6 Cognitive and genetic characteristics of people with aMCICitation1 and amnestic multiple-domain MCICitation13 elevate the risk of progression to dementia.Citation22 Due to environmental effectsCitation33 as well as genetic complexity,Citation6 finding a responsible single gene or allele to generate MCI seems difficult. Until now, only a small proportion of genetic-related late-life cognitive impairment has been identified.Citation22

The different fields of science such as psychiatry, neurology, neuropathology, neuroimaging, neuropsychology, geriatrics, clinical trials, and ethics are working eagerly to summarize the current state of MCI.Citation16 This present review intends to provide an up-to-date overview on MCI management.

Framework of MCI diagnosis

MCI is an intermediate stage of dementia, which increases the need for diagnostic tests and markers such as neuropsychological tests, neuroimaging, and biological markers.Citation6 The lack of specific tests, gradual loss of memory, health issues changing memory;Citation34 the absence of exact pathological changes in the brain;Citation12 and the lack of similar signs and symptoms make it more difficult to diagnose MCI. Consideration of memory loss as a normal event and a part of ageing is another limit in identifying MCI cases.Citation34 The individuals diagnosed with MCI have no dementia and no medical, neurologic, or psychiatric problem to cause memory loss. Diagnosis of MCI is based on subjective complaint of memory loss, memory impairment based on brief cognitive or neuropsychological testing, decline in normal function, and unchanged basic daily functioning.Citation8 However, there are some ways to diagnose MCI. One of the methods relies on asking questions about memory (language skills, recall, attention span, and visual-spatial abilities), medications, health status, and comorbidities (depression and emotional health concerns). Interviews with family members and close friends can also increase the chance to ascertain information about the patients’ memory, personality, and behavior changes. Diagnosis can be assured when this method is combined with additional tests and brain imaging techniques.Citation34

Biomarker assessment, clinical measurements, and imaging techniques are extra methods.Citation35 Biological markers such as tau protein increase the specificity and acuity of diagnosis to predict the risk of cognitive decline.Citation35 Acute phase proteins, cytokines, cholesterol, isoprostanes, homocysteine, and ApoE4 allele are more potential biomarkers for MCI and AD diagnosis.Citation36

The low plasma levels of amyloid beta (Aβ) including Aβ1–40, Aβ1–42, and Aβ1–42/Aβ1–40 ratio can indicate cognitive decline.Citation36 Aβ and tau levels such as Aβ1–42 and tau phosphorylated at threonine 181 (P-tau181p) in cerebrospinal fluid (CSF) are also used to diagnose MCI and AD with at least 85% sensitivity and 80% specificity.Citation37 Aβ42 factor is more important than P-tau181p in the diagnosis of MCI.Citation37 The levels of Aβ and tau in MCI are less than those in AD.Citation38,Citation39 In addition, these biomarkers can predict the risk of functional decline and MCI conversion to AD.Citation37 The lower level of Aβ in CSF and a high ratio of total-tau/Aβ can support the diagnosis of prodromal AD in cases with MCI.Citation18 Furthermore, finding plasma biomarkers such as epigenetic regulators including microRNA are useful to better diagnose individuals at a higher risk of MCI and developing AD in future.Citation40 Neuroimaging techniques are also used to diagnose MCI by measuring structural and functional parts of the brain ().Citation6 Imaging tests can show hippocampal volume loss and temporal lobe atrophy in MCI.Citation37 There are amyloid abnormalities in CSF and imaging tests in approximately 70%–74% of subjects with aMCI.Citation18

Table 2 List of some neuroimaging techniques to diagnose mild cognitive impairment

The combination of MRI and CSF tau/Aβ42 can provide a better prediction of MCI and its progression to ADCitation37 that is extremely helpful in developed countries compared to in the developing world.Citation37 Such difference is due to resource limitations and different cultural values, which limits the utility of MRI and CSF tests.Citation12,Citation35 Clinical assessment is used along with other methods to determine cognitive decline ().Citation12 Clinical tests are based on interviews to be used in clinical judgment and third-party information. Such tests can help to recognize any psychosocial impairment and the problems of neuropsychological function involving orientation, aphasia, apraxia, memory, calculation, constructional abilities, verbal abilities, and intellectual abilities.Citation28

Table 3 List of some clinical tests to diagnose mild cognitive impairment

All tests are used to identify cognitive decline, brain changes, and transitional phase towards AD, which lead to a proper characterization of disease, and its progressive phase in providing effective interventions.Citation12 Recognition of MCI makes it possible to delay the onset of dementia or even prevent disease via early diagnosis and probably potential treatment.Citation16 However, an accurate diagnosis is the key element in the practice of medicine for MCI, although etiological heterogeneityCitation41 limits the development of specific diagnostic criteria, specific therapeutic approaches, and the predictions of clinical progression.Citation42 MCI screening for early clinical dementia is recommended particularly for older persons above 75 years of age using blood tests and simple neuroimaging such as computed tomography brain scans.Citation43 It is, of course, not possible to use all tests; however, as much as possible, these tests give a good guideline for assessment of MCI.Citation6

Treatments

MCI has a greater risk of progression to dementia; therefore, it needs to be prevented or lowered.Citation1,Citation8 A suitable treatment is based on choosing the effective and appropriate strategies for the specific etiology of cognitive disorder.Citation1 At this time, there is no cure for MCI that stops or reverses it.Citation6 It has been suggested that antioxidants such as vitamin E, vitamin C, gingko biloba, and curcumin (from turmeric) are useful at the initial stages to reduce oxidative stress levels and ageing consequences.Citation6 For example, vitamin E is a dietary compound that can prevent or treat MCI or AD due to strong antioxidant properties.Citation44,Citation45 It seems that intake of antioxidants helps to reduce cognitive decline despite inconsistency among epidemiology data on antioxidants and cognitive function.Citation46

Pharmacological and nonpharmacological treatmentsCitation6 are used to prevent more reduction of cognition in MCICitation11 via focusing better and thinking clearly.Citation6 Pharmacotherapy is preferably limited to the patients who are at higher risk of transition to AD.Citation11,Citation47 Factors including limited options, medications side-effects, uncertain prognosis, and inappropriate social, psychological, and ethical consequences restrict the pharmacological treatment of MCI.Citation47 Some chemicals are suggested to treat MCI and prevent its conversion to AD (). A medication that is used to improve cognition is galantamine. This medication increases the rate of death and has no effect on the conversion rate from MCI to dementia; therefore, the balance of risks and benefits should be concerned for prescription. Acetylcholinesterase inhibitors are used in ApoE4 allele-positive patients with aMCI, who are at a higher risk of developing AD. However, the more popular treatments of MCI are nonpharmacologicalCitation6 such as autonomic training, eating habits, exercise (aerobic exercise), thinking processes, and social activities.Citation11 Such treatment can control psychological and physical comorbidities by having positive impacts on hyperlipidemia, isolation, depression, sleep quality, weight gain, social networking, and vascular risk factors like hypertension.Citation6

Table 4 List of some chemicals suggested for mild cognitive impairment treatment

Appropriate strategies to treat MCI and prevent the progressive decline of cognitive functions are the periodic monitoring of patients, providing lifestyle guidance, treating lifestyle-related diseases, and training on cognitive function.Citation11 Cognitive activities and training programs such as crossword puzzles, novels, and sudoku can also improve cognitive ability or slow down cognitive decline.Citation6 The preventive effect of intellectual activities on MCI or dementiaCitation48 is achieved by protecting against cognitive impairment,Citation49 brain disease, and severe neuropathology. The contribution of family members and close friends in the treatment of MCI is via their support, encouragement, patience, and respect.Citation34 However, the risk of MCI can be reduced by a Mediterranean dietCitation50 and moderate exercise as well as by interactive and mentally challenging activities.Citation51

The promotion of independence in communication and activities of daily living, control of vascular risk factors (hypertension, hyperlipidemia, diabetes mellitus), having a healthy lifestyle (physical activity, healthy diet, enough sleep, limited alcohol intake, smoking cessation), along with mental exercises (practicing puzzles, playing scrabble, reading, learning languages, playing musical instruments) are effective factors in the treatment of MCI.Citation52 Furthermore, periodic physician care of patients in 3–6 months intervals will help to improve cognition and delay the progression of disease into dementia.

Limitations and strengths of MCI research

There are some limitations that can affect studies about MCI. First, there is the lack of a specific tool for MCI diagnosis and determining its prevalence, especially in cases who delay or refuse to answer survey questions. Second, the exact classification of MCI requires more extensive measuring tests that are expensive and time consuming. The distribution of patients in the medical clinics is not equal; hence, it is difficult to categorize disease based on types and prescribed medications. In addition, the large population of patients limits the ability to clinically classify all in one study. Heterogeneity of samples also affects MCI studies due to their differences in origins, locations and cultures. The other limitation is the cross-sectional design of studies, which makes it difficult to identify the exact type and cause of MCI as well as the survival of patients. A confounding factor is the return of disease to a normal situation. The lack of specific criteria and specific cutoff points for MCI operationalization can restrict studies about the impairment of cognition. Thus, a wide heterogeneity in diagnosis, type of prescribed medications, severity of illness, and number of patients, as well as a variety of assessment tools can cause great impacts that limit such research. Despite all limitations, the studies about MCI are important to prevent its progression to dementia in future interventions. Research about MCI can be strengthened by having a large sample size containing a wide range of populations with cultural, economic, and social diversity. Pre-validated and standardized measurements strongly increase internal validity in studies and elevate consistency between countries, which can result in a common algorithm used to define MCI.

Conclusion and future works

All data from different countries can reflect the diversity of MCI in different regions in relation to demographic and cultural influences. Such information can be beneficial for both clinical and educational purposes. Our review has potential to improve the knowledge of a large group of people, including health care providers, policy-makers, MCI patients, and family members. In addition, it can increase the ability to identify variations in the utility of clinical diagnostic criteria. This review sheds light on the fundamental issue of developing MCI, although it seems relatively simple. It is necessary to investigate more on risk factors. It will be necessary in the future to determine standardized definitions and the diagnostic criteria for MCI and prodromal stages of AD in population-based studies and clinical trials. It is also necessary to find specific biomarkers, which help to correctly diagnose MCI and MCI converters to dementia. Clinical evidences and anatomical changes in the brain in specific cognitive deficits promote the improvement of imaging techniques, which results in a better assessment of different stages and types of MCI.

Disclosure

The authors report no conflicts of interest in this work.

References

  • DeCarliCMild cognitive impairment: prevalence, prognosis, aetiology, and treatmentLancet Neurol20032152112849297
  • RitchieKTouchonJMild cognitive impairment: conceptual basis and current nosological statusLancet200035522522810675135
  • KesterJDBenjaminASCastelADCraikFIMMemory in elderly peopleBaddeleyADKopelmanMDWilsonBAThe handbook of memory disorder2nd edLondonWiley2002543567
  • EtgenTSanderDBickelHFörstlHMild cognitive impairment and dementia: the importance of modifiable risk factorsDtsch Arztebl Int201110874375022163250
  • WoodfordHJGeorgeJCognitive assessment in the elderly: a review of clinical methodsQJM200710046948417566006
  • PintoCSubramanyamAAMild cognitive impairment: The dilemmaIndian J Psychiatry200951Suppl 1S44S5121416016
  • PetersenRCSmithGEWaringSCIvnikRJTangalosEGKokmenEMild cognitive impairment: clinical characterization and outcomeArch Neurol19995630330810190820
  • TriccoACSoobiahCLillieEUse of cognitive enhancers for mild cognitive impairment: protocol for a systematic review and network meta-analysisSyst Rev201212522647316
  • GauthierSReisbergBZaudigMMild cognitive impairmentLancet20063671262127016631882
  • RazaliRBaharudinAJaafarNRNFactors Associated with Mild Cognitive Impairment among Elderly Patients Attending Medical Clinics in Universiti Kebangsaan Malaysia Medical CentreSains Malaysiana201241641647
  • OdawaraTCautious notification and continual monitoring of patients with mild cognitive impairmentPsychogeriatrics20121213113222712649
  • AlbertMSBlackerDMild cognitive impairment and dementiaAnnu Rev Clin Psychol2006237938817716075
  • IrishMLawlorBACoenRFO’MaraSMEveryday episodic memory in amnestic mild cognitive impairment: a preliminary investigationBMC Neurosci2011128021816065
  • MorrisJCPriceJLPathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s diseaseJ Mol Neurosci20011710111811816784
  • CrookTBartusRTFerrisSHWhitehousePCohenGDGershonSAge-associated memory impairment: Proposed diagnostic criteria and measures of clinical change – report of a national institute of mental health work groupDev Neuropsychol198624261276
  • PetersenRCStevensJCGanguliMTangalosEGCummingsJLDeKoskySTPractice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2001561133114211342677
  • KlugerAGianutsosJGGolombJWagnerAJrWagnerDScheurichSClinical features of MCI: motor changesInt Psychogeriatr200820323918072982
  • WardAArrighiHMMichelsSCedarbaumJMMild cognitive impairment: disparity of incidence and prevalence estimatesAlzheimers Dement20128142122265588
  • Wada-IsoeKUemuraYNakashitaSPrevalence of Dementia and Mild Cognitive Impairment in the Rural Island Town of Ama-cho, JapanDement Geriatr Cogn Disord Extra20122190199
  • SosaALAlbaneseEStephanBCPrevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based studyPLoS medicine20129e100117022346736
  • RashidAAzizahARohanaSCognitive impairment among the elderly Malays living in rural MalaysiaMed J Malaysia201267187189
  • ReitzCMayeuxRUse of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementiaJ Alzheimers Dis20101922925120061642
  • EshkoorSAHamidTANudinSSMunCYDoes substance abuse contribute to further risk of falls in dementiaNeuropsychol Dev Cogn B Aging Neuropsychol Cogn20142131732423883099
  • VisserPJMild Cognitive ImpairmentMaastrichtNeuropsych Publishers200013496497
  • BruscoliMLovestoneSIs MCI really just Is MCI really just early dementia? A systematic review of conversion early dementia? A systematic review of conversion studiesInt Psychogeriatr20041612914015318760
  • PetersenRCMild cognitive impairment as a diagnostic entityJ Intern Med200425618319415324362
  • PanzaFD’IntronoAColaciccoAMCurrent epidemiology of mild cognitive impairment and other predementia syndromesAm J Geriat Psychiatry200513633644
  • BusseAAngermeyerMCRiedel-HellerSGProgression of mild cognitive impairment to dementia: a challenge to current thinkingBr J Psychiatry200618939940417077428
  • SmithGEPetersenRCParisiJEDefinition, course, and outcome of mild cognitive impairmentAging Neuropsychol C19963141147
  • NizamuddinMPopulation ageing: policy responses to population ageing in Asia and the PacificFifth Asian and Pacific Population Conference2000202595
  • EllisonJMA 60-year-old woman with mild memory impairment: review of mild cognitive impairmentJAMA20083001566157418768403
  • LopezOLKullerLHBeckerJTIncidence of dementia in mild cognitive impairment in the cardiovascular health study cognition studyArch Neurol20076441642017353386
  • EshkoorSAHamidTANudinSSMunCYThe effects of sleep quality, physical activity, and environmental quality on the risk of falls in dementiaAm J Alzheimers Dis Other Demen20132840340723698600
  • AustromMGLuYLong term caregiving: helping families of persons with mild cognitive impairment copeCurr Alzheimer Res2009639239819689239
  • LamLCTamCWLuiVWScreening of mild cognitive impairment in Chinese older adults – a multistage validation of the Chinese abbreviated mild cognitive impairment testNeuroepidemiology20083061218204291
  • SongFPoljakASmytheGASachdevPPlasma biomarkers for mild cognitive impairment and Alzheimer’s diseaseBrain Res Rev200961698019464319
  • TrojanowskiJQVandeersticheleHKoreckaMUpdate on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjectsAlzheimers Dement2010623023820451871
  • AndreasenNBlennowKCSF biomarkers for mild cognitive impairment and early Alzheimer’s diseaseClin Neurol Neurosurg200510716517315823670
  • BlennowKCSF biomarkers for mild cognitive impairmentJ Intern Med200425622423415324365
  • SheinermanKSTsivinskyVGCrawfordFMullanMJAbdullahLUmanskySRPlasma microRNA biomarkers for detection of mild cognitive impairmentAging (Albany NY)2012459060523001356
  • DuboisBAlbertMLAmnestic MCI or prodromal Alzheimer’s disease?Lancet Neurol2004324624815039037
  • PetersenRCDoodyRKurzACurrent concepts in mild cognitive impairmentArch Neurol2001581985199211735772
  • DaiDLMild Cognitive Impairment: A Clinical ApproachMed Bull20081391116
  • FarinaNIsaacMGClarkARRustedJTabetNVitamin E for Alzheimer’s dementia and mild cognitive impairmentCochrane Database Syst Rev201211CD00285423152215
  • DyskenMWSanoMAsthanaSEffect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trialJAMA2014311334424381967
  • WongSHRajikanRDasSAntioxidant intake and mild cognitive impairment among elderly people in Klang Valley: a pilot studySains Malaysiana201039689696
  • DaleWHoughamGWHillEKSachsGAHigh interest in screening and treatment for mild cognitive impairment in older adults: A pilot studyJ Am Geriatr Soc2006541388139416970647
  • HåkanssonKRovioSHelkalaELAssociation between midlife marital status and cognitive function in later life: population based cohort studyBMJ2009339b246219574312
  • ChenderesRMPodeaDMNanuPDMilaCP03-95 Mild cognitive impairment and intellectual activity in the elderlyEur Psychiatry200924S1094
  • RobertsROGedaYECerhanJRVegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairmentDement Geriatr Cogn Disord20102941342320502015
  • GedaYERobertsROKnopmanDSPhysical exercise, aging, and mild cognitive impairment: a population-based studyArch Neurol201067808620065133
  • AmbiggaDSuthaharARamliANgKRadziahAMarymolKDiagnosis and Management of Mild Cognitive Impairment in the Community: What is the Role of Primary Care Physician?Malays Fam Physician20116747825606229